Pham Nguyen, Thanh Phuong
Thibault, Dylan
Hamedani, Ali G.
Willis, Allison W.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS099129)
National Institute on Aging (K24AG075234)
Article History
Received: 30 May 2024
Accepted: 27 August 2024
First Online: 6 September 2024
Declarations
:
: The Institutional Review Board (IRB) of the University of Pennsylvania approved this survey (protocol #833498). The New England IRB approved the Fox Insight study. All Fox Insight participants gave informed consent, and if unable, a legal guardian gave consent by proxy at enrollment.
: Not applicable.
: Dr. Pham Nguyen was a member of the 2022-2023 Junior Investigator Intensive Program of the U.S. Deprescribing Research Network, which was funded by the National Institute on Aging [Grant # R24AG064025] and receives support from the National Institute of Health [Grants #1RF1NS132673-01, #R01NS099129, #R01AG02515215, #R01AG06458903] and Acadia Pharmaceuticals Inc., unrelated to this project. Dr. Hamedani receives financial support from the National Institutes of Health [Grant #K23EY033438] and the Michael J. Fox Foundation for Parkinson’s Research. Dr. Willis receives financial support from the National Institutes of Health [Grants #1RF1NS132673-01, #R01NS099129, #K24AG075234, #RF1NS132673], the Parkinson’s Foundation, Acadia Pharmaceuticals Inc., and the University of Pennsylvania. Mr. Thibault declared no competing interests for this work.